Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2

Priya Bhardwaj, Neil M Iyengar, Heba Zahid, Katharine M Carter, Dong Jun Byun, Man Ho Choi, Qi Sun, Oleksandr Savenkov, Charalambia Louka, Catherine Liu, Phoebe Piloco, Monica Acosta, Rohan Bareja, Olivier Elemento, Miguel Foronda, Lukas E Dow, Sofya Oshchepkova, Dilip D Giri, Michael Pollak, Xi Kathy Zhou, Benjamin D Hopkins, Ashley M Laughney, Melissa K Frey, Lora Hedrick Ellenson, Monica Morrow, Jason A Spector, Lewis C Cantley, Kristy A Brown

Obesity, defined as a body mass index (BMI) ≥ 30, is an established risk factor for breast cancer among women in the general population after menopause. Whether elevated BMI is a risk factor for women with a germline mutation in BRCA1 or BRCA2 is less clear because of inconsistent findings from epidemiological studies and a lack of mechanistic studies in this population. Here, we show that DNA damage in normal breast epithelia of women carrying a BRCA mutation is positively correlated with BMI and with biomarkers of metabolic dysfunction. In addition, RNA sequencing showed obesity-associated alterations to the breast adipose microenvironment of BRCA mutation carriers, including activation of estrogen biosynthesis, which affected neighboring breast epithelial cells. In breast tissue explants cultured from women carrying a BRCA mutation, we found that blockade of estrogen biosynthesis or estrogen receptor activity decreased DNA damage. Additional obesity-associated factors, including leptin and insulin, increased DNA damage in human BRCA heterozygous epithelial cells, and inhibiting the signaling of these factors with a leptin-neutralizing antibody or PI3K inhibitor, respectively, decreased DNA damage. Furthermore, we show that increased adiposity was associated with mammary gland DNA damage and increased penetrance of mammary tumors in Brca1+/- mice. Overall, our results provide mechanistic evidence in support of a link between elevated BMI and breast cancer development in BRCA mutation carriers. This suggests that maintaining a lower body weight or pharmacologically targeting estrogen or metabolic dysfunction may reduce the risk of breast cancer in this population.